Tech Company Financing Transactions
Kernal Biologics Funding Round
Kernal Biologics, based in Cambridge, received investment capital from Follicular Lymphoma Innovation.
Transaction Overview
Company Name
Announced On
11/17/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the development of KR-402, its new, mRNA-encoded CAR-T candidate for B-cell malignancies and autoimmune diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
At Kernal Bio, we aim to harness the power of our mRNA technology to provide cancer patients with treatments that give them the best chance of beating their disease -- while eliminating as many common side effects as possible. Our unique inside-out approach attacks diseases like cancer at the cellular level.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 11/17/2026: General Flash venture capital transaction
Next: 11/17/2026: Arva AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs








